Investigating new therapies for acute myeloid leukemia with RUNX1 mutations
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1
This study is looking at how certain changes in the RUNX1 gene affect acute myeloid leukemia (AML) and aims to find new treatments that work better for patients with these gene changes, helping to make cancer cells more vulnerable to therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10987034 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of RUNX1 mutations in acute myeloid leukemia (AML) and developing novel therapies targeting these mutations. Researchers will explore how these mutations affect blood cell formation and contribute to therapy resistance in patients. By using advanced techniques like shRNA-mediated knockdown and gene editing, the study aims to identify effective treatments that can improve outcomes for patients with AML expressing mutant RUNX1. The goal is to enhance the lethality of treatments specifically in cancer cells with these mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with acute myeloid leukemia who have somatic or germline RUNX1 mutations.
Not a fit: Patients without RUNX1 mutations or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with acute myeloid leukemia, particularly those with RUNX1 mutations.
How similar studies have performed: Other research has shown promising results in targeting genetic mutations in cancer, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Bhalla, Kapil — University of Tx Md Anderson Can Ctr
- Study coordinator: Bhalla, Kapil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.